Keytruda And The Surprising Fruits Of M&A
This article was originally published in Scrip
Similar fruits can grow in the most disparate soils. So it would seem when one considers the origins of Keytruda and Opdivo, the twin shining stars in the modern immuno-oncology firmament, owned by Merck and Co and Bristol-Myers Squibb, respectively.
Register for our free email digests: